Acasti Pharma Inc., a subsidiary of Neptune Technologies & Bioressources Inc. ("Neptune") /quotes/comstock/15*!nept/quotes/nls/nept (NEPT 1.40, +0.14, +11.11%) /quotes/comstock/11v!e:ntb (CA:NTB 1.46, 0.00, 0.00%) reports significant results on the effects of its anti-dyslipidemic investigational drug candidate CaPre(TM) on C-reactive protein (CRP) levels, a biomarker of Cardiovascular Disease risk (CVD) and associated with diabetes and obesity.
The study demonstrated that severe dyslipidemic and metabolic syndrome (pre-diabetic) subjects, treated once-daily with either 0.5g or 2.5g CaPre(TM) human equivalent dosing per day for 28 days, benefited from the treatment resulting in a reduction of CRP levels by 15% and 24%, respectively. It is recognized by the American Heart Association that testing CRP levels in the blood may be an additional way to assess cardiovascular disease risk. In addition, the prevalence of high CRP levels is accentuated in overweight and obese individuals now affecting 60% of the population of 20 years and over according to the Centers for Disease Control and Prevention (Atlanta, USA).
"The present results clearly suggest a beneficial lowering effect of CaPre(TM) on CRP. This observation, combined with our previous findings that CaPre(TM) reduces triglycerides and LDL-cholesterol (bad cholesterol) and elevates HDL-cholesterol (good cholesterol), indicates that CaPre(TM) offers a more complete protection against severe dyslipidemia and associated systemic inflammatory conditions as cardio metabolic syndrome," said Dr. Farhad Amiri, Associate-Director, Preclinical Studies, R&D.
"Accumulating evidence in the literature indicates that C-reactive protein may be as important as LDL-cholesterol in assessing the development of atherosclerosis ("hardening of the arteries") and heart disease," said Dr. Pierre Lemieux, Chief Operating Officer of Acasti. "Chronic inflammation is associated with the most prevalent health problems today such as obesity and diabetes. Similar to the JUPITER trial showing a CVD benefit of statin lowering CRP, a reduction in CRP by CaPre(TM), may constitute an additional tool in the systemic management of 800,000 myocardial infractions and 700,000 strokes that occur in the United States each year," he added.
Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipids products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular conditions within the over-the-counter, medical food and prescription drug markets.
NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.
"Neither NASDAQ nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."